Metformin inhibits ganglionic neurotransmission in renal nerves

Hypertension

Volumn 29, Issue 5, 1997, Pages 1173-1177

  Petersen, Jørgen Søberg ^b   Liu, Wen ^a   Kapusta, Daniel R ^a   Varner, Kurt J ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

diabetes mellitus; metformin; neurotransmission; sympathetic nerve activity

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; TRIMETAPHAN;

ANIMAL EXPERIMENT; ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; HYPERGLYCEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY NERVE; MALE; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD; SYMPATHETIC NERVE;

EID: 0031005003     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.5.1173     Document Type: Article

References (27)

1. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
2. De Fronzo RA, Goodman AM, the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
3. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allowed diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br J Med. 1995;310:83-88.
4. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F. Metformin for obese, insulin-treated diabetic patients: improvement of glycemic control and reduction of metabolic risk factors. Diabetes Care. 1993;16:1387-1390.
5. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16:1387-1390.
6. Petersen JS, DiBona GF. Acute sympathoinhibitory responses to metformin in spontaneously hypertensive rats. Hypertension. 1996; 27:619-625.
7. Muntzel M, Petersen JS. Metformin decreases arterial pressure by activating sympathetic withdrawal in spontaneously hypertensive rats. FASEB J. 1996;10:A568. Abstract.
8. Barajas L, Liu L, Powers K. Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol. 1992;70:735-749.
9. Schramm LP, Strack AM, Platt KB, Loewy AD. Peripheral and central pathways regulating the kidney: a study using pseudorabies virus. Brain Res. 1993;616:251-262.
10. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
11. Large WA, Sim JA. A comparison between mechanisms of actions of different nicotinic blocking agents on rat submandibular ganglia. Br J Pharmacol. 1986;89:538-592.
12. Chan JCN, Tomlinson B, Critchley JAJH, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and gliben-clamide in normotensive NIDDM patients. Diabetes Care. 1993;16: 1035-1038.
13. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral diabetic combination therapy with sulphonylureas and metformin. Diabete Metab. 1991;17:224-231.
14. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 1991;229:181-187.
15. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647-654.
16. Campbell IW, Duncan C, Patton NW, Broadhead T, Tucker GT, Woods HF. The effect of metformin on glycemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabet Med. 1987;4:337-341.
17. Gudbjörnsdottir S, Friberg P, Elam M, Attvall S, Lönnroth P, Wallin BG. The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Pressure. 1994;3:394-403.
18. Hermann LS, Schersten B, Bitzen P, Kjellström T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double blind controlled study. Diabetes Care. 1994;17:110-1109.
19. Semplicini A, Del Prato S, Giusto M, Campagnolo M, Palatini P, Rossi GP, Valle R, Dorella M, Albertini G, Pessina AC. Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives. J Hypertens. 1993;11(suppl 5):S276-S277.
20. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ, Vara E, Calle JR, Munguira ME, Maranes JP. Comparison between acarbose, metformin, and insulin treatment in type-2 diabetic patients with secondary failure to sulphonylurea treatment. Diabete Metab. 1995;21:256-260.
21. Morgan DA, Mark AL. Contrasting effects of metformin and ciglitazone on sympathetic nerve responses to insulin. FASEB J. 1993; 7:A653. Abstract.
22. Verma S, Bhanot S, McNeil JH. Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats. Am J Physiol. 1994;267:H1250-H1253.
23. Verma S, Bhanot S, McNeil JH. Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther. 1994;271:1334-1337.
24. Zhang HY, Reddy SR, Kotchen TA. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension. 1994;25:106-110.
25. DiBona GF. Renal neural mechanisms in salt-sensitive hypertension. Blood Pressure. 1995;4(suppl 2):81-87.
26. Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension. 1996;28:219-223.
27. Lembo G, Iaccarino G, Vecchione C, Rendina V, Frimarco B. Insulin modulation of vascular reactivity is already impaired in prehypertensive spontaneously hypertensive rats. Hypertension. 1995;26:290-293.